The Real Criteria for a Mounjaro Prescription (and the Biggest Myth About Them)

The myth: any BMI over 30 means you qualify automatically

This is the most common misunderstanding, and it's worth correcting before anything else. The licensed eligibility for tirzepatide does start at a BMI of 30, but a licence threshold and a prescription are two different things. A prescriber isn't simply ticking a BMI box; they're asking whether this medicine is clinically appropriate for this person, right now, given everything on their health record.

In practice that means someone with a BMI of 32 and no weight-related conditions may meet the technical threshold but still need a conversation about whether treatment is the right first step. Meanwhile, someone with a BMI of 28 and well-managed hypertension could meet the criteria under the licensed indication for BMI ≥27 with a relevant comorbidity. Whether you can get Mounjaro on prescription depends on the whole assessment, not a single figure. That nuance is what a good clinical review is for.

People often also assume that because Mounjaro is available privately, approval is lenient. In a properly run service it isn't. Photo-ID verification, a live weight check, a review of current medications and a full medical history form are all standard at nume (at nume) and a GPhC-registered Independent Prescriber reads every application personally the same day.

BMI thresholds, qualifying conditions and who the licence covers

The UK licence for Mounjaro covers adults aged 18 and over with a BMI of at least 30 kg/m², or a BMI of at least 27 kg/m² where at least one weight-related condition is present. The NHS tirzepatide information page lists the conditions that qualify: type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, and cardiovascular disease are the main ones, but prediabetes, high cholesterol and osteoarthritis are also relevant.

For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, UK guidance recognises that health risks associated with excess weight can arise at lower BMI values, and thresholds are adjusted accordingly, typically 2.5 kg/m² lower across the board. A prescriber will factor this in if it applies to you.

Mounjaro is not licensed for anyone under 18, and it is not recommended during pregnancy, breastfeeding or if you're actively trying to conceive. If you're using oral contraceptives, there's an additional practical step: NHS guidance advises adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because Mounjaro can temporarily reduce how well an oral pill is absorbed. This is the kind of detail a thorough prescriber will cover at assessment. You can find more on our weight-loss treatments page if you'd like to see how the consultation works in practice.

Conditions that rule Mounjaro out, and the ones that need a closer look

Some medical histories mean tirzepatide cannot safely be used. A personal or family history of medullary thyroid carcinoma (MTC), or a diagnosis of Multiple Endocrine Neoplasia type 2 (MEN2), are absolute contraindications. A history of serious pancreatitis, certain severe gastrointestinal conditions such as gastroparesis, and known hypersensitivity to tirzepatide or any component of the injection are also grounds for not prescribing.

Other situations call for extra clinical judgement rather than an outright no. Kidney disease, liver conditions, heart failure and the combination of Mounjaro with certain other diabetes medicines (particularly insulin or sulphonylureas) all warrant careful review and discussion. The prescriber's job is to weigh these factors, not to rubber-stamp a form. The Mounjaro prescription process at a reputable service should surface all of this, which is precisely why the assessment exists.

One quick check worth doing before you start any application: look the pharmacy up on the GPhC register at pharmacyregulation.org/registers. It takes under a minute and confirms the service you're using is a genuine, regulated UK pharmacy. Any seller offering tirzepatide without asking for a full medical history first is a serious red flag.

NHS criteria versus private criteria: they're not the same

The NHS applies a separate, stricter set of criteria for Mounjaro that sit on top of the licence. NICE's NHS criteria for tirzepatide currently require a BMI of at least 35 kg/m² plus at least four of five specified comorbidities for those accessing treatment through primary care from June 2025, with additional cohorts phasing in over the following two years. Most people who are curious about Mounjaro won't meet those NHS thresholds yet, or will face a significant wait if they do.

Private treatment through a regulated online pharmacy follows the licensed eligibility directly (BMI ≥30, or ≥27 with a qualifying condition) and does not require a GP referral or a wait. The clinical assessment is no less rigorous; it's simply not gatekept by commissioning cohorts. GP prescribing criteria are shifting as the NHS rolls the medicine out through primary care, so that picture will change, but for now, private is the main route for most people who qualify on clinical grounds but don't yet qualify on NHS grounds.

If cost is part of your thinking, the Mounjaro price comparison page sets out what typical private pricing looks like and what should be included in a legitimate service fee. And if you'd like to talk through whether you're likely to meet the criteria, our clinical team is available to review your application the same day.